These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17414574)

  • 1. "Flushing out" cytosine arabinoside from CSF to reverse neurotoxicity.
    Bleyer A
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):274. PubMed ID: 17414574
    [No Abstract]   [Full Text] [Related]  

  • 2. Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report.
    Pellier I; Leboucher B; Rachieru P; Ifrah N; Rialland X
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):837-9. PubMed ID: 17164656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anterior uveitis associated with high-dose cytosine arabinoside.
    Fintelmann RE; Qian Y; Skalet A; Jeng BH
    Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cerebellar toxicity of cytosine-arabinoside in a young man following cerebral anoxia].
    Beaudreuil J; Lortholary O; Jarrousse B; Salama J; Guillevin L; Casassus P
    Ann Med Interne (Paris); 1995; 146(8):597-8. PubMed ID: 8734092
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia.
    Openshaw H; Slatkin NE; Stein AS; Hinton DR; Forman SJ
    Cancer; 1996 Nov; 78(9):1899-905. PubMed ID: 8909309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe anterior uveitis as a complication of high-dose cytosine-arabinoside.
    Moberg J; Carlsson M; Holm C; Koranyi G
    Acta Ophthalmol; 2009 Nov; 87(8):922-3. PubMed ID: 19799589
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytarabine dose for acute myeloid leukemia.
    Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
    N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new pattern of cytosine-arabinoside-induced lung toxicity.
    Chagnon K; Boissel N; Raffoux E; Dombret H; Tazi A; Bergeron A
    Br J Haematol; 2009 Dec; 147(5):771-4. PubMed ID: 19735260
    [No Abstract]   [Full Text] [Related]  

  • 9. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.
    Friedman JH; Shetty N
    Mov Disord; 2001 May; 16(3):575-7. PubMed ID: 11391764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retreatment with low-dose cytarabine in patients with previous central nervous system toxicity.
    Olavarria E; Prieto E; Roman A
    Am J Hematol; 1997 Apr; 54(4):338. PubMed ID: 9092694
    [No Abstract]   [Full Text] [Related]  

  • 11. Transient Ara-C leukoencephalopathy: MR findings.
    Patel AG; Rao R
    J Comput Assist Tomogr; 1996; 20(1):161-2. PubMed ID: 8576470
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytarabine dose for acute myeloid leukemia.
    Mori J; Tsubokura M; Kami M
    N Engl J Med; 2011 Jun; 364(22):2166-7; author reply 2168-9. PubMed ID: 21631342
    [No Abstract]   [Full Text] [Related]  

  • 13. Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?
    Wiernik A; Sperr WR; Weisdorf D; Valent P; Ustun C
    Am J Hematol; 2013 Jun; 88(6):533-4. PubMed ID: 23526441
    [No Abstract]   [Full Text] [Related]  

  • 14. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
    Insiripong S; Thaisamakr S
    J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytarabine-induced neurotoxicity responding to methyl prednisolone.
    Malhotra P; Mahi S; Lal V; Kumari S; Jain S; Varma S
    Am J Hematol; 2004 Dec; 77(4):416. PubMed ID: 15551283
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
    Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
    Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy.
    Boesen P; Fallingborg J; Spaun E
    Acta Med Scand; 1988; 224(2):189-91. PubMed ID: 3166602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 19. Cerebellar dysfunction during high dose cytosine arabinoside therapy in a case of acute myelogenous leukaemia.
    Cold S
    Scand J Haematol; 1986 Feb; 36(2):165-7. PubMed ID: 3458292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
    Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
    Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.